Fig. 1
In vivo administration of VSSP reduces prostate tumor growth in Ptenpc−/−. a Schedule of treatment used in the pre-clinical trial in Ptenpc−/− mice. 9–12 weeks old mice were surgically castrated and 7 days after started the administration of VSSP (5 mg/kg, i.p, twice per week), αCXCR2 (100 mg/kg, orally, daily) or vehicle (PBS, 200 µL; i.p. or orally). After 12 weeks of treatment mice were euthanized and tumors were collected. b Prostate tumor volume of Ptenpc−/− mice treated with VSSP (n = 8), αCXCR2 (n = 14) or PBS (n = 17) after surgical castration. c FACS quantitation of TAMs (CD45+CD11b+Ly6G−F4/80+). d Phenotype of TAMs determined by FACS. e Schedule of treatment used in the pre-clinical trial with Ptenpc−/−; Trp53pc−/− mice. 11–14 weeks old Ptenpc−/−; Trp53pc−/− mice were treated with VSSP (5 mg/kg, i.p, twice per week) or PBS (200µL; i.p., twice per week). After 10 weeks of treatment mice were euthanized and tumors were collected. f Prostate tumor volume of Ptenpc−/−; Trp53pc−/− mice treated with VSSP (n = 6) or PBS (n = 6). Symbols indicates significant differences by Tukey test (*p < 0.05; **p < 0.01). CTX surgical castration, TAMs tumor-associated macrophages